Search

Your search keyword '"Kato, Hisamori"' showing total 152 results
Start Over Author "Kato, Hisamori"
152 results on '"Kato, Hisamori"'

3. Clinical characteristics and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma confirmed by central pathologic review: A multi-institutional retrospective study from the Japanese Clinical Oncology Group

Author

Kikuchi, Akira, Yoshida, Hiroshi, Tsuda, Hitoshi, Nishio, Shin, Suzuki, Shiro, Takehara, Kazuhiro, Kino, Nao, Sumi, Toshiyuki, Kato, Kazuyoshi, Yokoyama, Masatoshi, Nakamura, Kazuto, Takano, Masashi, Sato, Shinya, Kato, Hisamori, Tamate, Masato, Horie, Koji, Kato, Tomoyasu, Sakamoto, Atsuhiko, Fukunaga, Masaharu, Kaku, Tsunehisa, Yoshida, Masayuki, Yaegashi, Nobuo, and Satoh, Toyomi

Published
2023
Full Text
View/download PDF

5. Preliminary result of combined treatment with scanning carbon-ion radiotherapy and image-guided brachytherapy for locally advanced cervical adenocarcinoma

Author

Tsuchida, Keisuke, primary, Yoshida, Daisaku, additional, Shima, Satoshi, additional, Kusunoki, Terufumi, additional, Takayama, Yoshiki, additional, Koge, Hiroaki, additional, Kano, Kio, additional, Takakusagi, Yosuke, additional, Mizoguchi, Nobutaka, additional, Kamada, Tadashi, additional, Kusano, Yohsuke, additional, Kato, Hisamori, additional, and Katoh, Hiroyuki, additional

Published
2024
Full Text
View/download PDF

8. Use of clinical variables for preoperative prediction of lymph node metastasis in endometrial cancer

Author

Ueno, Yuta, primary, Yoshida, Emiko, additional, Nojiri, Shuko, additional, Kato, Tomoyasu, additional, Ohtsu, Takashi, additional, Takeshita, Toshiyuki, additional, Suzuki, Shunji, additional, Yoshida, Hiroshi, additional, Kato, Ken, additional, Itoh, Masayoshi, additional, Notomi, Tsuguto, additional, Usui, Kengo, additional, Sozu, Takashi, additional, Terao, Yasuhisa, additional, Kawaji, Hideya, additional, and Kato, Hisamori, additional

Published
2023
Full Text
View/download PDF

11. Does the extension of the type of hysterectomy contribute to the local control of endometrial cancer?

Author

Hasegawa, Tetsuya, Furugori, Megumi, Kubota, Kazumi, Asai-Sato, Mikiko, Yashiro-Kawano, Aiko, Kato, Hisamori, Oi, Yuka, Shigeta, Hiroyuki, Segawa, Keiko, Kitagawa, Masakazu, Mine, Yuko, Saji, Haruya, Numazaki, Reiko, Maruyama, Yasuyo, Ohnuma, Emi, Taniguchi, Hanako, Sugiura, Ken, Miyagi, Etsuko, Matsunaga, Tatsuya, and Yokohama City University Gynecologic Oncology Research Group (YCUGO-ReG)

Published
2019
Full Text
View/download PDF

13. Cancer cell‐derived CD69 induced under lipid and oxygen starvation promotes ovarian cancer progression via fibronectin

Author

Koizume, Shiro, primary, Kanayama, Tomohiko, additional, Kimura, Yayoi, additional, Hirano, Hisashi, additional, Takahashi, Tomoko, additional, Ota, Yukihide, additional, Miyazaki, Kaoru, additional, Yoshihara, Mitsuyo, additional, Nakamura, Yoshiyasu, additional, Yokose, Tomoyuki, additional, Kato, Hisamori, additional, Takenaka, Katsuya, additional, Sato, Shinya, additional, Tadokoro, Hiroko, additional, Miyagi, Etsuko, additional, and Miyagi, Yohei, additional

Published
2023
Full Text
View/download PDF

19. 2022-RA-801-ESGO Challenge to individualize surgical treatment for uterine cancer by intraoperative-prediction of lymph node metastasis using mRNA biomarker and clinical variables

Author

Yoshida, Emiko, primary, Ueno, Yuta, additional, Kato, Hisamori, additional, Kato, Tomoyasu, additional, Notomi, Tsuguto, additional, Ito, Yosuke, additional, Fujihara, Risa, additional, Hirayama, Takashi, additional, Fujino, Kazunari, additional, and Terao, Yasuhisa, additional

Published
2022
Full Text
View/download PDF

20. Differential diagnosis of uterine adenosarcoma: identification of JAZF1-BCORL1 rearrangement by comprehensive cancer genome profiling

Author

Hasegawa, Chie, primary, Washimi, Kota, additional, Hiroshima, Yukihiko, additional, Kasajima, Rika, additional, Kikuchi, Keiji, additional, Notomi, Tsuguto, additional, Kato, Hisamori, additional, Hiruma, Toru, additional, Sato, Shinya, additional, Okubo, Yoichiro, additional, Yoshioka, Emi, additional, Ono, Kyoko, additional, Miyagi, Yohei, additional, and Yokose, Tomoyuki, additional

Published
2022
Full Text
View/download PDF

22. Cancer cell‐derived CD69 induced under lipid and oxygen starvation promotes ovarian cancer progression through fibronectin.

Author

Koizume, Shiro, Kanayama, Tomohiko, Kimura, Yayoi, Hirano, Hisashi, Takahashi, Tomoko, Ota, Yukihide, Miyazaki, Kaoru, Yoshihara, Mitsuyo, Nakamura, Yoshiyasu, Yokose, Tomoyuki, Kato, Hisamori, Takenaka, Katsuya, Sato, Shinya, Tadokoro, Hiroko, Miyagi, Etsuko, and Miyagi, Yohei

Abstract

Cancer tissues generally have molecular oxygen and serum component deficiencies because of poor vascularization. Recently, we revealed that ICAM1 is strongly activated through lipophagy in ovarian clear cell carcinoma (CCC) cells in response to starvation of long‐chain fatty acids and oxygen and confers resistance to apoptosis caused by these harsh conditions. CD69 is a glycoprotein that is synthesized in immune cells and is associated with their activation through cellular signaling pathways. However, the expression and function of CD69 in nonhematological cells is unclear. Here, we report that CD69 is induced in CCC cells as in ICAM1. Mass spectrometry analysis of phosphorylated peptides followed by pathway analysis revealed that CD69 augments CCC cell binding to fibronectin (FN) in association with the phosphorylation of multiple cellular signaling molecules including the focal adhesion pathway. Furthermore, CD69 synthesized in CCC cells could facilitate cell survival because the CD69–FN axis can induce epithelial–mesenchymal transition. Experiments with surgically removed tumor samples revealed that CD69 is predominantly expressed in CCC tumor cells compared with other histological subtypes of epithelial ovarian cancer. Overall, our data suggest that cancer cell‐derived CD69 can contribute to CCC progression through FN. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study

Author

Yonemori, Kan, primary, Kuboki, Yasutoshi, additional, Hasegawa, Kosei, additional, Iwata, Takashi, additional, Kato, Hidenori, additional, Takehara, Kazuhiro, additional, Hirashima, Yasuyuki, additional, Kato, Hisamori, additional, Passey, Chaitali, additional, Buchbjerg, Jeppe Klint, additional, Harris, Jeffrey R., additional, Andreassen, Camilla Mondrup, additional, Nicacio, Leonardo, additional, Soumaoro, Ibrahima, additional, and Fujiwara, Keiichi, additional

Published
2022
Full Text
View/download PDF

24. Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079)

Author

Tanigawa, Terumi, primary, Takeshima, Nobuhiro, additional, Ishikawa, Hideki, additional, Nishio, Shin, additional, Usami, Tomoka, additional, Yamawaki, Takaharu, additional, Oishi, Tetsuro, additional, Ihira, Kei, additional, Kato, Hisamori, additional, Goto, Mayako, additional, Saito, Motoaki, additional, Taira, Yusuke, additional, Yokoyama, Masatoshi, additional, Shoji, Tadahiro, additional, Kondo, Eiji, additional, Mori, Atsushi, additional, Yokoi, Takeshi, additional, Iwasa-Inoue, Naomi, additional, Hirashima, Yasuyuki, additional, Nagasawa, Takayuki, additional, Takenaka, Motoki, additional, Mikami, Mikio, additional, Sugiyama, Toru, additional, and Enomoto, Takayuki, additional

Published
2022
Full Text
View/download PDF

25. Significance of positive peritoneal cytology for recurrence and survival in patients with endometrial cancer.

Author

Ueno, Yuta, Toyoshima, Masafumi, Shigemi, Daisuke, Yumori, Asuna, Wakabayashi, Reina, Kitagawa, Masakazu, Konnai, Katsuyuki, Onose, Ryo, Suzuki, Shunji, and Kato, Hisamori

Subjects
CANCER relapse, RETROSPECTIVE studies, REGRESSION analysis, PERITONEUM, CANCER patients, COMPARATIVE studies, ENDOMETRIAL tumors, DESCRIPTIVE statistics, CYTOLOGY
Abstract

Aim: This study aims to examine the association between malignant peritoneal cytology and prognosis in women with endometrial cancer. Methods: We retrospectively analyzed the records of patients with endometrial cancer who underwent surgery with intraoperative peritoneal cytology at our hospital between January 1988 and December 2012. All results were reclassified according to the 2009 International Federation of Gynecology and Obstetrics (FIGO) system, and the relation between intraoperative peritoneal cytology results and recurrence and prognosis was examined. Results: Of the 908 patients analyzed, 205 (22.6%) had positive peritoneal cytology. Patients with positive peritoneal cytology had significantly lower rates of recurrence‐free survival (RFS) and overall survival (OS) than those in the negative cytology group (both p < 0.001). Subgroup analysis of patients with FIGO stage I/II showed significantly lower RFS in the positive‐cytology group (p = 0.005), but there was no significant difference in OS (p = 0.637). In the patients with FIGO stage III/IV or patients classified as "high risk," the RFS and OS were significantly lower in the positive‐cytology group (both p < 0.001). Cox regression analysis identified positive peritoneal cytology as a significant predictor of recurrence in patients with FIGO stage I/II disease. Conclusions: Patients with positive peritoneal cytology for endometrial cancer have a high risk of recurrence, regardless of histopathologic type or FIGO stage. Peritoneal cytology has already been removed from the 2009 FIGO classification of endometrial cancer, but it may deserve reconsideration. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Interleukin-34 expression in ovarian cancer : a possible correlation with disease progression

Author

Endo, Hiraku, Hama, Naoki, Baghdadi, Muhammad, Ishikawa, Kozo, Otsuka, Ryo, Wada, Haruka, Asano, Hiroshi, Endo, Daisuke, Konno, Yosuke, Kato, Tatsuya, Watari, Hidemichi, Tozawa, Akiko, Suzuki, Nao, Yokose, Tomoyuki, Takano, Atsushi, Kato, Hisamori, Miyagi, Yohei, Daigo, Yataro, and Seino, Ken-Ichiro

Subjects
disease stage, ovarian cancer, interleukin-34, overall survival, progression-free survival
Abstract

Ovarian cancer is the second-most lethal gynecological malignancy and the seventh-commonest cause of cancer-related death in women around the world. Most of the ovarian cancer patients are diagnosed at advanced stages and suffer from recurrence after primary cytoreductive surgery and standard first-line chemotherapy. Thus, the successful management of ovarian cancer patients requires the identification of factors that contribute to progression and relapse. Interleukin-34 (IL-34) is a novel cytokine that acts as a tissue-specific ligand of colony-stimulating factor-1 receptor (CSF-1R). In cancer, IL-34 exerts pro-tumorigenic functions that promote tumor growth, metastasis, angiogenesis, immune suppression and therapeutic resistance. In this study, we evaluate the impact of IL-34 on progression and survival of ovarian cancer patients. First, IL-34 was found to be expressed in several human ovarian cancer cell lines and cancer tissues from patients. The expression of IL-34 was enhanced by cytotoxic chemotherapy in ovarian cancer cell lines and cancer tissues from chemotherapy-treated ovarian cancer patients. Importantly, high IL-34 expression correlated with worse progression-free survival (PFS) and overall survival in different cohorts. The assessment of PFS based on a combination between IL34 expression and other related genes such as CSF1R and CD163 helped further to reach more statistical significance compared with IL34 alone. Furthermore, in the murine ovarian cancer cell HM-1 in vivo model, it was suggested that IL-34-derived tumor cells was correlated with tumor progression and survival by modulating the immune environment. Collectively, these findings indicate a possible correlation between IL-34 expression and disease progression in ovarian cancer patients and the mouse model.

Published
2020

27. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

Author

Hamanishi, Junzo, primary, Takeshima, Nobuhiro, additional, Katsumata, Noriyuki, additional, Ushijima, Kimio, additional, Kimura, Tadashi, additional, Takeuchi, Satoshi, additional, Matsumoto, Koji, additional, Ito, Kimihiko, additional, Mandai, Masaki, additional, Nakai, Hidekatsu, additional, Sakuragi, Noriaki, additional, Watari, Hidemichi, additional, Takahashi, Nobutaka, additional, Kato, Hidenori, additional, Hasegawa, Kosei, additional, Yonemori, Kan, additional, Mizuno, Mika, additional, Takehara, Kazuhiro, additional, Niikura, Hitoshi, additional, Sawasaki, Takashi, additional, Nakao, Sari, additional, Saito, Toshiaki, additional, Enomoto, Takayuki, additional, Nagase, Satoru, additional, Suzuki, Nao, additional, Matsumoto, Takashi, additional, Kondo, Eiji, additional, Sonoda, Kenzo, additional, Aihara, Satomi, additional, Aoki, Yoichi, additional, Okamoto, Aikou, additional, Takano, Hirokuni, additional, Kobayashi, Hiroshi, additional, Kato, Hisamori, additional, Terai, Yoshito, additional, Takazawa, Akira, additional, Takahashi, Yusuke, additional, Namba, Yoshinobu, additional, Aoki, Daisuke, additional, Fujiwara, Keiichi, additional, Sugiyama, Toru, additional, and Konishi, Ikuo, additional

Published
2021
Full Text
View/download PDF

32. Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women.

Author

Onuki, Mamiko, Yamamoto, Kasumi, Yahata, Hideaki, Kanao, Hiroyuki, Yokota, Harushige, Kato, Hisamori, Shimamoto, Kumi, Takehara, Kazuhiro, Kamiura, Shoji, Tsuda, Naotake, Takei, Yuji, Shigeta, Shogo, Matsumura, Noriomi, Yoshida, Hiroyuki, Motohara, Takeshi, Watari, Hidemichi, Nakamura, Keiichiro, Ueda, Akihiko, Tasaka, Nobutaka, and Ishikawa, Mitsuya

Abstract

In Japan, the National Immunization Program against human papillomavirus (HPV) targets girls aged 12‐16 years, and catch‐up vaccination is recommended for young women up to age 26 years. Because HPV infection rates increase soon after sexual debut, we evaluated HPV vaccine effectiveness by age at first vaccination. Along with vaccination history, HPV genotyping results from 5795 women younger than 40 years diagnosed with cervical intraepithelial neoplasia grade 2‐3 (CIN2‐3), adenocarcinoma in situ (AIS), or invasive cervical cancer were analyzed. The attribution of vaccine‐targeted types HPV16 or HPV18 to CIN2‐3/AIS was 47.0% for unvaccinated women (n = 4297), but 0.0%, 13.0%, 35.7%, and 39.6% for women vaccinated at ages 12‐15 years (n = 36), 16‐18 years (n = 23), 19–22 years (n = 14), and older than 22 years (n = 91), respectively, indicating the greater effectiveness of HPV vaccination among those initiating vaccination at age 18 years or younger (P <.001). This finding was supported by age at first sexual intercourse; among women with CIN2‐3/AIS, only 9.2% were sexually active by age 14 years, but the percentage quickly increased to 47.2% by age 16 and 77.1% by age 18. Additionally, the HPV16/18 prevalence in CIN2‐3/AIS was 0.0%, 12.5%, and 40.0% for women vaccinated before (n = 16), within 3 years (n = 8), and more than 3 years after (n = 15) first intercourse, respectively (P =.004). In conclusion, our data appear to support routine HPV vaccination for girls aged 12‐14 years and catch‐up vaccination for adolescents aged 18 years and younger in Japan. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

33. Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix

Author

Ota, Yukihide, primary, Koizume, Shiro, additional, Nakamura, Yoshiyasu, additional, Yoshihara, Mitsuyo, additional, Takahashi, Tomoko, additional, Sato, Shinya, additional, Myoba, Shohei, additional, Ohtake, Norihisa, additional, Kato, Hisamori, additional, Yokose, Tomoyuki, additional, Miyagi, Etsuko, additional, and Miyagi, Yohei, additional

Published
2021
Full Text
View/download PDF

34. Human papillomavirus genotype contribution to cervical cancer and precancer: Implications for screening and vaccination in Japan

Author

Onuki, Mamiko, primary, Matsumoto, Koji, additional, Iwata, Takashi, additional, Yamamoto, Kasumi, additional, Aoki, Yoichi, additional, Maenohara, Shoji, additional, Tsuda, Naotake, additional, Kamiura, Shoji, additional, Takehara, Kazuhiro, additional, Horie, Koji, additional, Tasaka, Nobutaka, additional, Yahata, Hideaki, additional, Takei, Yuji, additional, Kato, Hisamori, additional, Motohara, Takeshi, additional, Nakamura, Keiichiro, additional, Ishikawa, Mitsuya, additional, Kato, Tatsuya, additional, Yoshida, Hiroyuki, additional, Matsumura, Noriomi, additional, Nakai, Hidekatsu, additional, Shigeta, Shogo, additional, Takahashi, Fumiaki, additional, Noda, Kiichiro, additional, Yaegashi, Nobuo, additional, and Yoshikawa, Hiroyuki, additional

Published
2020
Full Text
View/download PDF

35. Tissue factor pathway inhibitor II as a specific biomarker for pre-operative prediction of clear-cell carcinoma of the ovary.

Author

Miyagi, Etsuko, primary, Arakawa, Noriaki, additional, Ruiz Yokota, Naho, additional, Yamanaka, Takeharu, additional, Sakamaki, Kentaro, additional, Miyagi, Yohei, additional, Yamaguchi, Satoshi, additional, Nagao, Shoji, additional, Yamada, Yuki, additional, Hirashima, Yasuyuki, additional, Kasamatsu, Yuka, additional, Kato, Hisamori, additional, Kitagawa, Masakazu, additional, and Kobayashi, Hiroshi, additional

Published
2020
Full Text
View/download PDF

36. Interleukin-34 expression in ovarian cancer: a possible correlation with disease progression

Author

Endo, Hiraku, primary, Hama, Naoki, additional, Baghdadi, Muhammad, additional, Ishikawa, Kozo, additional, Otsuka, Ryo, additional, Wada, Haruka, additional, Asano, Hiroshi, additional, Endo, Daisuke, additional, Konno, Yosuke, additional, Kato, Tatsuya, additional, Watari, Hidemichi, additional, Tozawa, Akiko, additional, Suzuki, Nao, additional, Yokose, Tomoyuki, additional, Takano, Atsushi, additional, Kato, Hisamori, additional, Miyagi, Yohei, additional, Daigo, Yataro, additional, and Seino, Ken-ichiro, additional

Published
2019
Full Text
View/download PDF

37. Changes in the Clinicopathological Demographics of Vulvar Cancer in Japan: Increasing Oldest-Old, Stage Shifting, and Decreasing Cohort-Level Survival †

Author

Nishio, Shin, primary, Matsuo, Koji, additional, Shibata, Takeo, additional, Yamaguchi, Satoshi, additional, Kanao, Hiroyuki, additional, Takehara, Kazuhiro, additional, Kado, Nobuhiro, additional, Tozawa, Akiko, additional, Tokunaga, Hideki, additional, Matsunaga, Tatsuya, additional, Kato, Hisamori, additional, Horie, Koji, additional, Kikuchi, Akira, additional, Enomoto, Takayuki, additional, and Mikami, Mikio, additional

Published
2019
Full Text
View/download PDF

40. Aberrant Nuclear Localization of aPKCλ/ι is Associated With Poorer Prognosis in Uterine Cervical Cancer

Author

Tokinaga-Uchiyama, Aya, primary, Mizushima, Taichi, additional, Akimoto, Kazunori, additional, Nagashima, Yoji, additional, Sasaki, Kazunori, additional, Nakaya, Masa-aki, additional, Ohashi, Kenichi, additional, Kubota, Kazumi, additional, Maruyama, Yasuyo, additional, Kato, Hisamori, additional, Hirahara, Fumiki, additional, Miyagi, Etsuko, additional, Ohno, Shigeo, additional, and Asai-Sato, Mikiko, additional

Published
2019
Full Text
View/download PDF

44. Investigation of the clinicopathological features of vulva cancer: A retrospective survey of the JGOG Net Work study.

Author

Nishio, Shin, primary, Shibata, Takeo, additional, Yamaguchi, Satoshi, additional, Kanao, Hiroyuki, additional, Kojima, Atsumi, additional, Takekuma, Munetaka, additional, Tozawa, Akiko, additional, Tokunaga, Hideki, additional, Miyagi, Etsuko, additional, Kato, Hisamori, additional, Kurihara, Kazuko, additional, Yanase, Toru, additional, Mikami, Mikio, additional, and Sugiyama, Toru, additional

Published
2017
Full Text
View/download PDF

46. Impact of lower co-payments on risk-reducing salpingo-oophorectomy and BRCAtesting in Japan

Author

Konnai, Katsuyuki, Fujiwara, Hiroyuki, Kitagawa, Masakazu, Wakabayashi, Reina, Yumori, Asuna, Notomi, Tsuguto, Onose, Ryo, Kato, Hisamori, and Narimatsu, Hiroto

Abstract

Background: In April 2020, insurance coverage for risk-reducing salpingo-oophorectomy (RRSO) for breast cancer patients with hereditary breast and ovarian cancer (HBOC) syndrome and BRCAtesting were started in Japan. We investigated the impact of insurance coverage on the number of RRSO and BRCAtests performed. Methods: The subjects were 370 breast cancer patients and 23 of their relatives who received genetic counseling at our institution between April 2014 and December 2021. Finally, 349 patients and 15 relatives were analyzed. We retrospectively compared the number of BRCAtests, RRSO, insurance status, and co-payment of medical expenses before and after insurance coverage based on medical records. Results: In the 6-year pre-coverage period, 226 patients (mean: 37/year) received genetic counseling and 106 (17/year) received BRCAtesting. In the 21-month post-coverage period, 161 patients (92/year) received genetic counseling and 127 (72/year) received BRCAtesting. The rate of testing/counseling significantly increased in the post-coverage period (46.9% vs. 78.8%; p&lt; .001). The number of patients who were diagnosed with HBOC were 24 (4/year) and 18 (10/year) and RRSO was performed for 7 (1/year) and 11 (6/year) patients in the pre- and post-coverage periods, respectively. The rate of RRSO/HBOC was significantly increased in the post-coverage period (29.1% vs. 61.1%; p= 0.039). RRSO patients' co-payment rates decreased from 64% to 25% pre- and post-coverage. Conclusions: Our findings suggest that decreased co-payments were the primary reason for these increases. Insurance coverage is an important factor when promoting preventive medical services such as RRSO.

Published
2023
Full Text
View/download PDF

48. A Phase II Study of Paclitaxel and Carboplatin with a Biweekly Schedule in Patients with Epithelial Ovarian Cancer: Gynecologic Cancer Network Trial

Author

Yoneyama, Koichi, primary, Konishi, Hideki, additional, Yahata, Tetsuro, additional, Fujita, Kazuyuki, additional, Aoki, Yoichi, additional, Doi, Daisuke, additional, Matsushima, Takashi, additional, Kodama, Shoji, additional, Honma, Shigeru, additional, Kato, Hisamori, additional, Nakayama, Hiroki, additional, Kamoi, Seiryu, additional, Asakura, Hirobumi, additional, Takeshita, Toshiyuki, additional, and Tanaka, Kenichi, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results